Hsieh Ching-Jung, Wang Pei-Wen, Liu Rue-Tsuan, Tung Shih-Chen, Chien Wen-Yen, Chen Jung-Fu, Chen Chen-Hsiong, Kuo Ming-Chun, Hu Ya-Hui
Division of Edocrinology and Metabolosm, Department of Internal Medicine, Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niao-Sung Hsiang, Kaohsiung Hsien 83305, Taiwan.
Diabetes Res Clin Pract. 2005 Jan;67(1):78-83. doi: 10.1016/j.diabres.2004.05.012.
Orlistat lowers lipids and improves insulin sensitivity, but its effect on other metabolic syndrome related parameters is not known. To assess its influence on adiponectin, high sensitive C-reactive protein (hs-CRP) and other metabolic syndrome related parameters, this study enrolled 106 participants in a weight-reduction program and categorized them into a group of 51 who had been treated with orlistat 360 mg/day for one year and a group of 55 age and sex and body mass index (BMI) matched controls. The orlistat group had greater changes in BMI, % body fat (% BF), waist circumference, and insulin resistance, hs-CRP, leptin and adiponectin levels after one year on the program than the controls. After adjusting for % BF and waist circumference, change of serum leptin and adiponectin levels remained significantly different. It was found that orlistat could effectively manage obesity related co-morbidities, especially insulin resistance and atherosclerosis risk. It decreases leptin and increases adiponectin independent of % BF and waist circumference. Therefore, orlistat appears to have anti-diabetic and anti-atherogenic properties and may help prevent metabolic syndrome in the overweight people.
奥利司他可降低血脂并改善胰岛素敏感性，但其对其他与代谢综合征相关参数的影响尚不清楚。为评估其对脂联素、高敏C反应蛋白（hs-CRP）及其他与代谢综合征相关参数的影响，本研究招募了106名参加减肥计划的参与者，并将他们分为两组，一组51人，接受每日360毫克奥利司他治疗一年；另一组55人，为年龄、性别和体重指数（BMI）相匹配的对照组。在该计划实施一年后，奥利司他组在BMI、体脂百分比（%BF）、腰围以及胰岛素抵抗、hs-CRP、瘦素和脂联素水平方面的变化均大于对照组。在校正%BF和腰围后，血清瘦素和脂联素水平的变化仍存在显著差异。研究发现，奥利司他可有效控制与肥胖相关的合并症，尤其是胰岛素抵抗和动脉粥样硬化风险。它可降低瘦素水平并增加脂联素水平，且不受%BF和腰围的影响。因此，奥利司他似乎具有抗糖尿病和抗动脉粥样硬化特性，可能有助于预防超重人群的代谢综合征。
